Opthea, a biopharmaceutical firm that develops drugs for eye diseases, has completed patient enrolment in the Phase IIa trial of OPT-302 for diabetic macular edema (DME).

The randomised, dose expansion study involves determining the safety and efficacy of OPT-302 when administered in combination with aflibercept (Eylea) for treating DME.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) that prevents the activity of VEGF-C and VEGF-D, proteins involved in vessel growth and leakage in the eye.

The combination of OPT-302 and a VEGF-A inhibitor has shown potential to improve clinical outcomes in DME patients.

Around two million people globally are affected by DME, which is one of the major causes of vision loss among the working-age population.

Opthea CEO Dr Megan Baldwin said: “We are excited about the potential for OPT-302 in DME given the positive outcomes of our Phase IIb wet AMD study, as well as our earlier positive Phase Ib clinical results which showed dose escalation of OPT-302 combination therapy was well tolerated with improved visual and anatomic outcomes in patients with treatment-resistant and persistent DME.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The ongoing Phase IIa DME study is further evaluating OPT-302 combination therapy in a larger patient population to confirm these observations and we look forward to reporting topline data in the second quarter of 2020.”

The Phase IIa trial is designed to feature around 108 patients with persistent centre-involved DME undergoing regular anti-VEGF-A monotherapy.

Subjects will be treated with either aflibercept (2 mg) + OPT-302 (2 mg) or aflibercept monotherapy.

The primary endpoint of the study is the proportion of patients receiving a combination of OPT-302 and aflibercept, showing a five letter gain in visual acuity from baseline at week 12.

Secondary endpoints include mean visual acuity, macular thickness, improvement in diabetic retinopathy severity score and durability of response.